Table 2.
Patient and Clinical Characteristics and Treatment Details by Cohort
| Variable | No CTX (n = 366,575) | CTX (n = 995) | P* |
|---|---|---|---|
| Age at diagnosis, median, y | 61 | 60 | < 0.001 |
| Race, No. (%) | |||
| White | 304,387 (83.0) | 862 (86.6) | 0.007 |
| Black | 45,367 (12.4) | 92 (9.3) | |
| Others/Unknown | 16,821 (4.6) | 41 (4.1) | |
| Charlson-Deyo Score, No. (%) | |||
| 0 | 307,154 (83.8) | 852 (85.6) | 0.113 |
| 1 | 52,957 (14.4) | 122 (12.3) | |
| 2+ | 6,464 (1.8) | 21 (2.1) | |
| Facility Type, No. (%) | |||
| Non-Academic/Research Program | 210,830 (57.6) | 334 (33.6) | < 0.001 |
| Academic/Research Program | 155,393 (42.4) | 659 (66.3) | |
| Year of Diagnosis, No. (%) | |||
| ≥ 2004 – ≤ 2007 | 129,192 (35.2) | 501 (50.4) | < 0.001 |
| > 2007 – ≤ 2009 | 83,964 (22.9) | 220 (22.1) | |
| > 2009 – ≤ 2011 | 83,900 (22.9) | 162 (16.3) | |
| > 2011 – ≤ 2013 | 69,519 (19.0) | 112 (11.3) | |
| AJCC clinical T stage, No. (%) | |||
| 1 | 213,891 (58.4) | 328 (33.0) | < 0.001 |
| 2 | 89,747 (24.5) | 319 (32.1) | |
| 3 | 10,243 (2.8) | 164 (16.5) | |
| 4 | 358 (0.1) | 15 (1.5) | |
| Unknown | 52,336 (14.3) | 169 (17.0) | |
| AJCC clinical N stage, No. (%) | |||
| 0 | 282,538 (77.1) | 663 (66.6) | < 0.001 |
| 1 | 1,067 (0.3) | 47 (4.7) | |
| Unknown | 82,970 (22.6) | 285 (28.6) | |
| AJCC pathologic T stage, No. (%) | |||
| 1–2 | 26,1170 (71.2) | 242 (24.3) | < 0.001 |
| 3 | 93,604 (25.5) | 630 (63.3) | |
| 4 | 2,113 (0.6) | 38 (3.8) | |
| Unknown | 9,688 (2.6) | 85 (8.5) | |
| AJCC pathologic N stage, No. (%) | |||
| 0 | 263,117 (71.8) | 623 (62.6) | < 0.001 |
| 1 | 9,745 (2.7) | 253 (25.4) | |
| Unknown | 93,713 (25.6) | 119 (12.0) | |
| Gleason Score, No. (%) | |||
| 2–7 | 315,957 (86.2) | 348 (35.0) | < 0.001 |
| 8–10 | 45,214 (12.3) | 585 (58.8) | |
| Unknown | 5,404 (1.5) | 62 (6.2) | |
| PSA, No. (%) | |||
| < 10 | 34,719 (9.5) | 187 (18.8) | < 0.001 |
| ≤ 10- < 20 | 264,260 (72.1) | 530 (53.3) | |
| ≥ 20 | 24,624 (6.7) | 198 (19.9) | |
| Unknown | 42,972 (11.7) | 80 (8.0) | |
| Surgical Margin, No. (%) | |||
| Negative | 275,028 (75.0) | 529 (53.2) | < 0.001 |
| Positive | 87,590 (23.9) | 414 (41.6) | |
| Unknown | 3,957 (1.1) | 52 (5.2) | |
| RT, No. (%) | |||
| No RT | 344,656 (94.0) | 727 (73.1) | < 0.001 |
| Adjuvant RT | 15,781 (4.3) | 196 (19.7) | |
| RT–adjuvant criteria not met | 6,138 (1.7) | 72 (7.2) | |
| ADT, No. (%) | |||
| No | 338,908 (92.4) | 346 (34.8) | < 0.001 |
| Yes | 18,193 (5.0) | 634 (63.7) | |
| Unknown | 9,474 (2.6) | 15 (1.5) |
Abbreviations: CTX, Chemotherapy; AJCC, American Joint Committee on Cancer; PSA, Prostate-specific antigen; RT, Radiation therapy; ADT, Androgen deprivation therapy
*
Bolded P Values are significant